



Drug Design and Development for Diagnosis and Treatment of Neuropsychiatric Diseases

Guest Editors:

Dr. Marco Bortolato

Department of Pharmacology
and Toxicology, College of
Pharmacy, University of Utah,
Salt Lake City, UT, USA

Assoc. Prof. Simona Scheggi

Dept. Molecular and
Developmental Medicine,
University of Siena, Siena, Italy

Deadline for manuscript
submissions:

closed (31 October 2021)

Message from the Guest Editors

Although the incidence and economic burden of neuropsychiatric disorders are increasing worldwide, therapeutic tools for these diseases remain unsatisfactory. For example, no effective pharmacological treatments for Alzheimer's disease, autism spectrum disorder, negative and cognitive symptoms of schizophrenia are available. Unfortunately, because of the complexity of these conditions, many clinical trials have failed, and several pharmaceutical companies have recently reduced or ceased their investment in neuroscience research. This background underscores the urgent need for tangible progress and advances in neuropsychopharmacological research.

This Special Issue of *Biomolecules* is dedicated to novel directions in drug design and development for neuropsychiatric diseases. The main goal is to showcase the ongoing progress in the identification of molecular targets for the treatment of epilepsy, movement disorders, dementia, neuromuscular diseases, as well as depression, schizophrenia, anxiety, autism, and drug abuse and dependence.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Biochemistry*)

Contact Us

Biomolecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
[X@Biomol_MDPI](https://twitter.com/Biomol_MDPI)